Car T-cell therapy for acute myeloid leukemia (AML)
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of cell therapy using natural killer (NK) cells that target a protein called CD33 found on AML cells. The goal is to see if these cells can help treat leukemia that has not responded to standard treatments, and you would receive a stem cell transplant afterward to help your bone marrow recover.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of leukemia called AML that has returned or has not cleared up after treatment.
- You must be between 1 and 39 years old.
- You must have a stem cell donor identified and be willing to have a stem cell transplant if needed.
- You need to have acceptable kidney, liver, heart, and lung function.
- If you have had a stem cell transplant, it must have been at least 90 days before starting this trial.
- If you are of childbearing age, you must agree to use effective birth control for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy, called CAR-T, that uses your own immune cells to find and attack leukemia cells. It's designed for people whose AML has come back or hasn't responded to standard treatments. The cells are modified to target a protein called CD33 on leukemia cells.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
This trial tests a new approach for people with acute myeloid leukemia (AML) that has not gotten better with standard treatments. First, you receive modified stem cells, then specially designed immune cells (CAR T cells) that target a protein called CD33 on leukemia cells. The goal is to see if this combination can safely help your body fight the leukemia.
This trial tests a personalized cell therapy called CD33 CAR-T for people whose acute myeloid leukemia has come back or isn't responding to standard treatments. The goal is to see if it's safe and can help eliminate leukemia cells that carry the CD33 protein.
This Phase 1 study tests a personalized immune-cell treatment (CD33 CAR T cells) for adults with AML that has returned or did not respond to treatment. It aims to see how safe the therapy is and how well it works for AML cells that carry the CD33 marker.
This Phase 1 study tests a type of lab-made immune cell therapy (CAR T cells) made from your T cells to treat AML that has relapsed or not responded, as long as the cancer shows a marker called CD33. The goal is to see if the treatment is safe and can help control AML after it returns or resists standard therapy.
Hear when a new Relapsed/Refractory AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.